Immuneering Corporation Operating Lease, Payments
Immuneering Corporation (IMRX) reported Operating Lease, Payments of $378.10 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- Immuneering Corporation operating lease, payments for the quarter ending 2026-06-30 was $189.05K, a 3.00% increase year-over-year.
- Immuneering Corporation operating lease, payments for the quarter ending 2026-03-31 was $189.05K, a 3.00% increase year-over-year.
- Immuneering Corporation operating lease, payments for the quarter ending 2025-12-31 was $189.05K, a 3.00% increase year-over-year.
- Immuneering Corporation operating lease, payments for the quarter ending 2025-09-30 was $183.55K, a 3.00% increase year-over-year.
- Immuneering Corporation operating lease, payments for fiscal 2025 was $739.69K, a 0.98% increase from fiscal 2024.
- Immuneering Corporation operating lease, payments for fiscal 2024 was $732.55K, a 13.15% decline from fiscal 2023.
- Immuneering Corporation operating lease, payments for fiscal 2023 was $843.46K, a 38.32% increase from fiscal 2022.
- Immuneering Corporation operating lease, payments for fiscal 2022 was $609.79K, a 446.76% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $189.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $378.10K 10-Q · filed 2026-08-05 | $567.15K derived: sum of 3 quarters · filed 2026-08-05 | $750.70K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $189.05K 10-Q · filed 2026-05-15 | $378.10K derived: sum of 2 quarters · filed 2026-05-15 | $561.65K derived: sum of 3 quarters · filed 2026-05-15 | $745.19K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $189.05K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $372.60K derived: sum of 2 quarters · filed 2026-03-06 | $556.14K derived: sum of 3 quarters · filed 2026-08-05 | $739.69K 10-K · filed 2026-03-06 |
| 2025-09-30 | $183.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $367.09K derived: sum of 2 quarters · filed 2026-08-05 | $550.64K 10-Q · filed 2025-11-12 | $734.18K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $183.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $367.09K 10-Q · filed 2026-08-05 | $550.64K derived: sum of 3 quarters · filed 2026-08-05 | $728.84K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $183.55K 10-Q · filed 2026-05-15 | $367.09K derived: sum of 2 quarters · filed 2026-05-15 | $545.29K derived: sum of 3 quarters · filed 2026-05-15 | $723.49K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $183.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $361.75K derived: sum of 2 quarters · filed 2026-03-06 | $539.95K derived: sum of 3 quarters · filed 2026-03-06 | $732.55K 10-K · filed 2026-03-06 |
| 2024-09-30 | $178.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $356.40K derived: sum of 2 quarters · filed 2025-11-12 | $549.00K 10-Q · filed 2025-11-12 | $741.60K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $178.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $370.80K 10-Q · filed 2025-08-13 | $563.40K derived: sum of 3 quarters · filed 2025-08-13 | $780.50K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $192.60K 10-Q · filed 2025-05-05 | $385.20K derived: sum of 2 quarters · filed 2025-05-05 | $602.30K derived: sum of 3 quarters · filed 2025-05-05 | $819.41K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $192.60K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $409.70K derived: sum of 2 quarters · filed 2025-03-20 | $626.81K derived: sum of 3 quarters · filed 2025-03-20 | $843.46K 10-K · filed 2025-03-20 |
| 2023-09-30 | $217.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $434.21K derived: sum of 2 quarters · filed 2024-11-13 | $650.86K 10-Q · filed 2024-11-13 | $780.68K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $217.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $433.76K 10-Q · filed 2024-08-06 | $563.57K derived: sum of 3 quarters · filed 2024-08-06 | $715.30K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $216.65K 10-Q · filed 2024-05-07 | $346.47K derived: sum of 2 quarters · filed 2024-05-07 | $498.19K derived: sum of 3 quarters · filed 2024-05-07 | $662.47K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $129.81K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $281.54K derived: sum of 2 quarters · filed 2024-03-01 | $445.81K derived: sum of 3 quarters · filed 2024-03-01 | $609.79K 10-K · filed 2024-03-01 |
| 2022-09-30 | $151.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $316.00K derived: sum of 2 quarters · filed 2023-11-09 | $479.98K 10-Q · filed 2023-11-09 | $508.34K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $164.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $328.25K 10-Q · filed 2023-08-03 | $356.62K derived: sum of 3 quarters · filed 2023-08-03 | $384.34K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $163.97K 10-Q · filed 2023-05-04 | $192.34K derived: sum of 2 quarters · filed 2023-05-04 | $220.06K derived: sum of 3 quarters · filed 2023-05-04 | $247.78K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $28.37K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $56.09K derived: sum of 2 quarters · filed 2023-03-06 | $83.81K derived: sum of 3 quarters · filed 2023-03-06 | $111.53K 10-K · filed 2023-03-06 |
| 2021-09-30 | $27.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $55.44K derived: sum of 2 quarters · filed 2022-11-10 | $83.16K 10-Q · filed 2022-11-10 | $109.43K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $27.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $55.44K 10-Q · filed 2022-08-10 | $81.71K derived: sum of 3 quarters · filed 2022-08-10 | $92.51K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $27.72K 10-Q · filed 2022-05-10 | $53.99K derived: sum of 2 quarters · filed 2022-05-10 | $64.79K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $26.27K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $37.07K derived: sum of 2 quarters · filed 2022-03-10 | $58.67K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $10.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $32.40K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $21.60K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |